Originally published In Press as doi:10.1074/jbc.M200460200 on February 25, 2002
J. Biol. Chem., Vol. 277, Issue 19, 16403-16411, May 10, 2002
Mapping the Binding Site of a Human
ether-a-go-go-related Gene-specific Peptide Toxin
(ErgTx) to the Channel's Outer Vestibule*
Liliana
Pardo-Lopez
§,
Mei
Zhang
,
Jie
Liu
,
Min
Jiang
,
Lourival D.
Possani§, and
Gea-Ny
Tseng
¶
From the
Department of Physiology, Virginia
Commonwealth University, Richmond, Virginia 23298 and the
§ Institute of Biotechnology, National Autonomous University
of Mexico, Cuernavaca 62210, Mexico
Received for publication, January 16, 2002, and in revised form, February 19, 2002
 |
ABSTRACT |
The goals of this study are to investigate the
mechanism and site of action whereby a human
ether-a-go-go-related gene (HERG)-specific scorpion peptide
toxin, ErgTx, suppresses HERG current. We apply cysteine-scanning
mutagenesis to the S5-P and P-S6 linkers of HERG and examine the
resulting changes in ErgTx potency. Data are compared with the
characteristics of charybdotoxin (ChTx, or its analogs) binding to the
Shaker channel. ErgTx binds to the outer vestibule of HERG but may not
physically occlude the pore. In contrast to ChTx·Shaker interaction,
elevating [K]o (from 2 to 98 mM) does not
affect ErgTx potency, and through-solution electrostatic forces only
play a minor role in influencing ErgTx·HERG interaction.
Cysteine mutations of three positions in S5-P linker (Trp-585, Gly-590,
and Ile-593) and 1 position in P-S6 linker (Pro-632) induce
profound changes in ErgTx binding (
G > 2 kcal/mol). We propose that the long S5-P linker of the HERG channel
forms an amphipathic
-helix that, together with the P-S6 linker,
forms a hydrophobic ErgTx binding site. This study paves the way for future mutant cycle analysis of interacting residues in the
ErgTx·HERG complex, which, in conjunction with NMR determination of
the ErgTx solution structure, will yield information about the topology of HERG's outer vestibule.
 |
INTRODUCTION |
The rapid delayed rectifier
(IKr)1 is an
important repolarizing current in many regions of the heart (1). The
major subunit that forms the IKr channel in human heart is
HERG (2). Inherited mutations in HERG have been identified and linked
to congenital long QT syndrome (LQT2) (2, 3). Furthermore, drugs that suppress IKr have been linked to "acquired LQT" (3).
These all point to the critical role played by IKr in
maintaining cardiac electrical stability. Therefore, information about
the structure of the IKr/HERG channel is important. Such
information will help in rational drug design for agents that are
useful for combating some forms of LQT syndrome (IKr/HERG
agonists), or for agents with zero or low risk for inducing acquired
LQT syndrome (no effects on IKr/HERG).
One of the most critical factors in determining IKr/HERG
function is its C-type inactivation process. This is the basis for the
"inward rectification" property of IKr/HERG, which is
important for shaping the action potentials in the heart. Inward
rectification dictates that there is little or no outward
IKr at positive plateau voltages (important for maintaining
the plateau phase) but large outward IKr during phase 3 (ensuring efficient repolarization back to the resting membrane
potential). Furthermore, the C-type inactivation process in the
IKr/HERG channel appears to be intimately related to
channel sensitivity to many different drugs (4-6). C-type inactivation
results from conformational changes in the outer mouth region of the
channel, which prevent current flow through the pore (7). Therefore, an
important target for structural analysis is the outer mouth region of
the IKr/HERG channel.
There is a general consensus that the outer vestibules of various
potassium channels share a common architecture (8-10). Indeed, homology modeling of outer vestibules of mammalian voltage-gated K+ (Kv) channels based on the crystal structure of KcsA
(9), a bacterial proton-gated potassium channel, has been successful in
several cases (10). However, such a strategy may not be applicable to
the HERG channel. First, the C-type inactivation in the
IKr/HERG channel is unique among all potassium channels
that have this gating process: C-type inactivation in
IKr/HERG is extremely fast in onset and in reversal and is
strongly voltage-dependent (11). These unique kinetic
features suggest that conformational changes in the outer mouth region
of HERG during membrane depolarization may be different from those of
the other channels. Second, HERG has an unusually long S5-P linker (43 amino acids), much longer than the 14- to 18-amino acid S5-P linker
seen in most other Kv channels, as well as the so-called "turret"
of KcsA (see Fig. 1A). We have shown that mutations in the
middle of HERG's S5-P linker, far away from the P (pore) loop in the
one-dimensional sequence, can have profound effects on the outer mouth
properties of the channel (12). There have been no reports on similar
effects of mutations in the middle of S5-P linker for other Kv
channels. Thus, the S5-P linker of HERG may play a unique structural
and functional role. Understanding such a role may provide answers to
questions such as why the C-type inactivation in the HERG channel has
such unique kinetic properties and how C-type inactivation is related
to the channel's sensitivity to various drugs.
Peptide toxins have been very useful tools in structural analysis of
potassium channels, well before the data of KscA crystal structure were
available (13, 14). Many short peptide scorpion toxins (
-KTx) are
available that can block various potassium channels with differences in
specificity and potency (13-15). Many
-KTx toxins have six
cysteines, forming three disulfide bridges (15). They have a
well-conserved positive residue (Lys-27 in ChTx) that serves to plug
the channel pore (Fig. 1B) (16). ErgTx is purified from
Centruroides noxius Hoffmann (GenBankTM
accession number CnErg1). It has 42 amino acids and 4 disulfide bonds
(17). Its amino acid sequence and disulfide bond pattern are not
homologous to those of representative
-KTx toxins shown in Fig.
1B. Previous work has shown that ErgTx is a potent blocker of HERG expressed in mammalian cells and native IKr in
guinea pig ventricular myocytes (IC50 in the low nanomolar
range) (18). It does not block IKs, IK, ATP,
IRK1, or EAG at 1 µM (18). Recently, we
showed that ErgTx sensitivity may be determined by the S5-P linker of
the HERG channel (19).
Due to the four disulfide bonds, ErgTx should have a compact and rigid
structure, amenable to NMR analysis of its solution structure. Our
ultimate goal is to map the ErgTx binding site on HERG and to identify
amino acid pairs that interact with each other across the toxin-channel
interface (20, 21). In this way, we hope to obtain a "footprint" of
the interaction surface of ErgTx on HERG and to derive the
three-dimensional arrangement of relevant residues on the outer
vestibule of this channel. This study is a first step toward that goal.
We applied cysteine-scanning mutagenesis, replacing all residues in the
outer vestibule region of HERG by cysteine one at a time, and studied
how these mutations affect ErgTx binding to the channel. We chose
cysteine, instead of alanine (22) or lysine (23), for two reasons.
First, the cysteine side chain is small, hydrophobic, and usually well
tolerated. Thus, it increases our chance of studying more mutant
channels. Second, cysteine side chains can be specifically modified by
methanethiosulfonate reagents. This will allow us to use different
strategies to estimate the distances between channel residues of
interests and the toxin binding site (21, 24). Based on these data, we
propose that the central region of HERG's S5-P linker forms an
amphipathic
-helix that interacts with the pore of the channel to
form the ErgTx binding site.
 |
EXPERIMENTAL PROCEDURES |
ErgTx Purification--
Venom was purified from scorpions
Centruroides noxius as described previously (17, 18) with
minor modifications. Briefly, crude venom was dissolved in water and
centrifuged at 10,000 × g for 15 min. The supernatant
was lyophilized and kept at
20 °C until final purification. After
Sephadex G-50 gel filtration, fraction II was directly applied to a
semi-preparative C18 reverse-phase column (Vydac, Hesperia, CA) and
eluted with a linear gradient from 5% of solvent A (0.12%
trifluoroacetic acid in water) to 60% solvent B (0.10%
trifluoroacetic acid in acetonitrile) over 90 min. The component eluted
at ~30 min was further chromatographed by high performance liquid
chromatography using an analytical C18 reverse-phase column. This gave
a major pure component (ErgTx), whose primary structure was obtained by
direct amino acid sequencing and by mass spectrometry (Fig.
1B) (17).
Molecular Biology--
HERG in a vector pGH19 was a kind gift of
Dr. Gail Robertson (University of Wisconsin-Madison). We subcloned the
HERG cDNA sequence (GenBankTM accession number U04270)
into the KpnI/XbaI site of a vector, pAlterMax,
which was required for the oligonucleotide-directed mutagenesis
procedure with a commercial kit (Altered Site II in vitro
mutagenesis system, Promega). Cysteine substitution mutations were
confirmed by direct DNA sequencing around the mutation sites. In most
cases, two separate colonies from each mutant were used for cRNA
transcription and oocyte expression. No differences were seen in the
phenotype of channels translated from the two cRNAs. For transcription,
wild-type (WT) and mutant HERG sequences in the pAlterMax vector were
linearized with NotI and transcribed using the T7 RNA
polymerase and a commercial kit (mMESSAGE mMACHINE, Ambion, Austin,
TX). All cRNA samples were quantified by denaturing RNA gels using
densitometry (ChemiImager model 4400,
-Innotech Corp.).
Oocyte Preparation and Injection--
Oocyte isolation and cRNA
injection were as described previously (25). Briefly, stage V oocytes
were isolated from follicular cell layer after mild collagenase
digestion and injected with cRNA solution using a Drummond digital
microdispenser. The injection volume was ~40 nl/oocyte, equivalent to
cRNA of 12-18 ng/oocyte.
Electrophysiological Experiments--
Three to five days after
cRNA injection, channel function was studied using the
two-microelectrode voltage clamp method as previously described (26).
During recordings, oocytes were superfused with a low-Cl ND96 solution
at room temperature. For experiments shown in Fig. 5, oocytes were not
superfused but were placed in the bath solution of a fixed volume (1 ml). ErgTx was dissolved in sterile bovine serum albumin (0.1 mg/ml)
solution at 2 µM and frozen in small aliquots. An aliquot
was thawed and used for experiments in <2 days without refreezing.
After control data were obtained, 5 µl of the ErgTx stock solution
was added to the bath solution (1 ml) to reach a final concentration of
10 nM. Repetitive pipetting was needed to ensure complete
equilibration of ErgTx in the bath solution. Toxin effects were
evaluated when steady state was reached (4-10 min). Voltage clamp
protocol generation and data acquisition were controlled by pClamp 5.5 (Axon Instruments). Data analysis was performed with pClamp 6 or 8, Excel (Microsoft) and PeakFit (Jandel Scientific). Specific protocols
and methods of data analysis are described in the figure legends. Where
appropriate, data are presented as mean ± S.E. Statistical
analysis was performed with one-way analysis of variance, followed by
Dunn's test (SigmaStat 2.0, SPSS).
 |
RESULTS |
Effects of Mutations in the Extracellular Linkers Suggest a Unique
Outer Vestibule Structure in the HERG Channel--
Fig. 2A
(panels a and c) shows the hallmark of wild-type
(WT) HERG currents: strong inward rectification due to rapid onset and
reversal of C-type inactivation in a voltage-dependent
manner. A depolarization pulse to +60 mV elicited little outward
current because of C-type inactivation. Subsequent repolarization to
+40 to
60 mV induced outward tail currents with a distinct rising phase (recovery from C-type inactivation). This led to a prominent negative slope in the tail I-V relationship (+60 to
60 mV, Fig. 2A, panel c). At more negative voltages, tail
currents became less outward and reversed at
100 mV (reversal
potential or Erev), close to the Nernst
K+ equilibrium potential (EK ~
105 mV in 2 mM [K]o).
Replacing histidine at position 587 to lysine (H587K, Fig. 2,
top), disrupted both the C-type inactivation process and the K+ selectivity of the pore. Current traces from H587K were
elicited by the same voltage clamp protocol as that used for WT HERG
(Fig. 2A, panel b). The step to +60 mV induced a
prominent outward current. Subsequent repolarization steps elicited
smaller outward currents that reversed between
10 and
20 mV. The
I-V relationship of H587K was almost linear in the voltage range
between
140 and 0 mV, with an upward turn at more positive voltages
(Fig. 2A, panel c). Therefore, the C-type
inactivation process was disrupted in H587K. Furthermore, removing
extracellular Na+ ions shifted the
Erev of H587K in the negative direction to about
60 mV (Fig. 2A, panel d), indicating that
external Na+ ions contributed significantly to currents
through the H587K channel pore. The calculated K+ to
Na+ permeability ratio
(PK:PNa) for H587K was
1.5 ± 0.1, much lower than that of the WT HERG (191 ± 91).
These changes in H587K were not due to the added permanent positive
charge, because increasing the protonation of H587 in WT HERG (by
changing the extracellular pH from 8.5 to 6.5) did not affect the
C-type inactivation process or the K:Na selectivity of the pore (27).
Furthermore, replacing His-587 with proline creates the same phenotype
as H587K (12). These observations indicate that the extracellular S5-P
linker of HERG, or at least the middle of this linker including
position 587, participates in conformational changes that determine the channel's outer mouth properties. There has been no report on similar
effects of mutations made in the S5-P linker of the Shaker channel on
the channel's outer mouth properties.
Fig. 2B illustrates another example of differences between
HERG and Shaker in their outer mouth properties. Position 449 in the
Shaker channel is located at the external entrance to the pore,
corresponding to position 631 of the HERG channel (Fig. 1A). It is an important
determinant of channel sensitivity to external TEA (28). Replacing the
threonine residue at this position with an aromatic residue (T449Y and
T449F) greatly enhances TEA binding (due to a stabilizing interaction
between positively charged TEA and
-electrons of the aromatic ring
at 449), while replacing Thr-449 with a positively charged residue
(T449K) has the opposite effect (due to electrostatic repulsion) (28).
We tested the effects of mutating the equivalent residue in the HERG
channel (Ser-631) on TEA potency (29). TEA blocked the outer mouth of the WT HERG channel with an IC50 of ~50 mM.
This is reflected by the decrease of outward tail current at
80 mV in
Fig. 2B (panel a).
The appearance of a prominent outward peak and the higher level of
outward current at +20 mV in the presence of TEA was due to an
interference of C-type inactivation by TEA bound to the outer mouth of
the channel (7). Surprisingly, replacing Ser-631 with an aromatic
residue (S631Y) reduced the sensitivity to external TEA (Fig.
2B, panel b). Furthermore, replacing Ser-631 with
a negatively charged residue (S631E) or a positively charged residue
(S631K) reduced the sensitivity to TEA. There is no difference in TEA
sensitivity between these two mutants. These data suggest that the
outer mouth configuration in the HERG channel differs significantly
from that of the Shaker channel so that the side chain at position 631 is shielded from bound TEA.

View larger version (49K):
[in this window]
[in a new window]
|
Fig. 1.
A, alignment of amino acid sequences in
the outer vestibule region of representative potassium channels with
that of HERG. The end of S5, P-loop and the beginning of S6 are
underlined; S5-P linker (corresponding to the "turret"
of KcsA) and P-S6 linker are marked. Shaded residues signify
the "GXG" motif of potassium channel signature sequence.
Note that, compared with the lengths of S5-P linker in these
representative potassium channels (14 or 18 residues), the S5-P linker
in HERG is much longer (43 residues). A putative amphipathic -helix
(positions 583-595) is shown as an insert. Positions in HERG examined
in this study are those from 571 to 613 and from 631 to 638 (numbers marked at top). B, alignment of amino
acid sequences of representative -KTx with that of ErgTx.
Abbreviations are: charybdotoxin (ChTx or
-KTx1.1), noxiustoxin (Ntx or
-KTx2.1), and agiotoxin 2 (AgTx2 or
-KTx3.2). Cysteines are boxed and connected to
illustrate disulfide bridges. The well-conserved lysine residues in
-KTx (Lys-27 in ChTx) crucial for the pore blockade activity are
highlighted by the shaded area. The histidine
(His-29, H) in ErgTx is also highlighted. In both
panels, alignment was performed using the ClustalV method. Gaps (.) are
inserted to enhance alignment.
|
|

View larger version (27K):
[in this window]
[in a new window]
|
Fig. 2.
Effects of mutations in the S5-P and P-S6
linkers on outer mouth properties of HERG and on TEA blockade.
Top: Partial HERG amino acid sequence. Positions examined
here (587 and 631) are marked. A, replacing His-587 with
lysine (H587K) destroys C-type inactivation and K+
selectivity. Panels a and b depict current traces
of WT and H587K HERG channels elicited by the voltage clamp protocol
shown at the top. Panel c shows the complete tail
I-V relationships for WT and H587K (n = 15 and 6).
Panel d shows that removing extracellular Na+
ions shifts the reversal potential (Erev) of
H587K from 15 to 60 mV. Inset: H587K current traces
before and after Na removal
(Vr 60 mV). B, replacing Ser-631
with tyrosine (S631Y), glutamate (S631E), or lysine (S631K) reduces
HERG sensitivity to extracellular TEA. Panels a-d show
current traces elicited by the voltage clamp protocol depicted at the
top before (thin traces) and after (thick
traces) adding TEA (50 mM) to the bath solution (with
equimolar [Na]o reduction). The channel types are marked.
Panel e summarizes the fractions of current not suppressed
by TEAo (ITEA/IC, ratio of peak tail
current amplitudes in the presence and absence of TEA). The
numbers of measurements are shown in parentheses.
Experiments were conducted in 2 mM [K]o.
|
|
ErgTx Selectivity--
Fig. 3 shows
that ErgTx potently suppressed the HERG current amplitude. The
suppressing effect could be detected at 1 nM ErgTx. However, ErgTx did not affect Kv1.4, Kv4.3, Kv2.1, or KvLQT1 even at 50 nM. This apparent selectivity, by itself, is not conclusive evidence for a unique outer vestibule structure in the HERG channel among the potassium channels examined here. Therefore, we further investigated the mechanism by which ErgTx suppresses HERG current, and
positions in HERG that are important for ErgTx binding. These features
are compared with those of ChTx (or its analogs) blockade of the Shaker
(or Shaker-like) channel. In the latter cases, the mechanism and
site of action of the toxins have been well characterized (16, 22-24).
Such a comparison will help us deduce how and where ErgTx binds to the
HERG channel and reduces the current.

View larger version (22K):
[in this window]
[in a new window]
|
Fig. 3.
Selectivity of ErgTx blockade of potassium
channels. Shown are time courses of changes in current amplitude
recorded from oocytes expressing different potassium channel subunits
before and after exposure to various concentrations of ErgTx (denoted
by different symbols, shown at top right).
Current amplitudes were normalized by that of the first current. Shown
in the inset of each panel are two current traces recorded
in the absence (thin trace) and presence (thick
trace) of 20 nM ErgTx. The following recording
conditions and pulse protocols were used: WT HERG, 98 mM
[K]o, tail current at 80 mV after a 1-s pulse to +20 mV;
Kv1.4 and Kv4.3, 2 mM [K]o, peak test pulse
current at +60 mV; Kv2.1 and KvLQT1, 2 mM [K]o,
current at the end of 1-s test pulse to +20 mV. The following are
species and sources of the potassium channel subunit clones used:
Kv1.4, rat, from Dr. J. Tseng-Crank (Eli Lilly); Kv4.3, rat, from Dr.
P. Serodio (Columbia University); Kv2.1, rat, from Dr. R. H. Joho
(University of Texas Southwestern Medical Center); KvLQT1, human, from
Dr. M. C. Sanguinetti (University of Utah).
|
|
Concentration Dependence of ErgTx Suppression of HERG--
Fig.
4A illustrates a
representative time course of changes in HERG current amplitude when
the oocyte was exposed to increasing concentrations of ErgTx (1-100
nM) and after wash out of the toxin. Currents were elicited
by repetitive depolarization pulses from Vh
80
to +20 mV for 1 s applied once every minute. The peak tail current
amplitudes before ErgTx application (Ic) and that at the steady state of ErgTx effect (Itx) were used to measure the
fraction of unblocked channels (Itx/Ic). ErgTx
suppressed HERG current in a concentration-dependent
manner. The effect was totally reversible. The data points can be well
fit with Equation 1,

View larger version (24K):
[in this window]
[in a new window]
|
Fig. 4.
ErgTx suppresses WT HERG current amplitude in
a dose-dependent and reversible manner, and elevating
[K]o from 2 to 98 mM does not affect toxin
binding. A, time course of a representative experiment
in 2 mM [K]o. Currents were elicited using the
pulse protocol shown in the inset, applied once per minute.
Peak tail current amplitudes were measured and normalized by the
control current amplitude just prior to ErgTx application, and plotted
against time of recording. The ErgTx concentrations are marked. The
dotted line connecting data points before and after ErgTx
exposure is the sloping baseline used for estimating current
suppression. Selected current traces are shown above the time course,
marked by letters a-e corresponding to those shown along
the time course. B, dose-response relationship of ErgTx
suppression of WT HERG. The fraction of remaining current at the steady
state of ErgTx blockade (Itx/Ic) is plotted
against ErgTx concentration on a logarithmic scale. Data are averaged
from experiments done in 2 mM [K]o (open
circles, with S.E. bars, n = 4) or in 98 mM [K]o (open square with S.E. bar, 10 nM ErgTx, n = 6). Individual measurements
in 98 mM [K]o at various ErgTx concentrations are
shown as smaller symbols (three experiments, represented by
different symbols). Data points obtained in 2 mM
[K]o are fit with Equation 1 (see text), where
Amax is the fraction of current sensitive to
ErgTx and Kd is the dissociation constant. The curve
superimposed on the data points is calculated with Equation 1 using the
best-fit parameter values listed in the inset.
|
|
|
(Eq. 1)
|
where Amax is the fraction of
current sensitive to ErgTx (93 ± 3%), and
Kd is the dissociation constant (6.45 ± 1.03 nM).
It is important to note that there is a residual current (on average
~10% of control) not suppressed by high concentrations of ErgTx.
This is clearly shown in Fig. 4A: increasing [ErgTx] from
50 to 100 nM induced little further suppression of the
current. In the presence of 100 nM ErgTx, the current's
waveform resembled that of the control current (showing C-type
inactivation and a high K+ selectivity, trace d
of Fig. 4A). Therefore, this cannot be due to an
ErgTx-insensitive background or "leak" conductance. Instead, it
suggests that ErgTx did not totally occlude the HERG pore. This is
different from ChTx blockade of the Shaker channel: Lys-27 of
ChTx binds and plugs the channel pore completely (22, 23). The
difference between ErgTx suppression of HERG and ChTx blockade of
Shaker is consistent with the lack of a "Lys-27-equivalent" in the ErgTx sequence (Fig. 1B).
Lack of [K]o Sensitivity in ErgTx·HERG
Interaction--
Fig. 4B also shows that ErgTx potency was
not affected by elevating [K]o from 2 to 98 mM.
This is distinctly different from the situation of ChTx blockade of the
Shaker channel. In this case, Lys-27 of ChTx is critical for
Ko sensitivity (16, 22). It is suggested that Lys-27 of
ChTx plugs the potassium channel pore by binding to a site close to
K+ binding site within the pore (16, 22). Elevating
[K]o increases K+ occupancy inside the pore, and
the resulting electrostatic repulsion between K+ ions and
Lys-27 of ChTx destabilizes toxin binding. The lack of Ko
sensitivity in ErgTx suppression of HERG is again consistent with the
lack of a Lys-27-equivalent residue in ErgTx and with the suggestion
that ErgTx does not physically plug the HERG pore.
Cysteine Scanning Mutagenesis Detects Positions Critical for ErgTx
Binding to HERG--
Studies of toxin binding to potassium channels
have implicated the S5-P linker (turret of KcsA, Fig. 1A)
and P-S6 linker as important components of toxin binding site (23, 24).
Therefore, we performed cysteine-scanning mutagenesis by replacing all
residues in the S5-P linker (positions 571-613, 43 residues) and the
P-S6 linker (positions 631 to 638, 8 residues) of HERG with
cysteine one at a time and studied the resulting effects on current
suppression by ErgTx.
Out of 51 positions mutated, six mutants were poorly or not expressed
(N573C, K595C, P605C, N633C, E637C, and K638C). Of the remaining 45 mutants, the ErgTx potency was evaluated in 98 mM [K]o using the same voltage clamp protocol as shown in Fig.
4A. One ErgTx concentration (10 nM) was used in
all measurements, and the Kd values were calculated
using the following modified Equation 2,
|
(Eq. 2)
|
The assumption is that the maximal effects in all cases were a
90% suppression (Fig. 4). This is valid because WT HERG has an
IC50 of 7.2 ± 1.1 nM when estimated using
Equation 2 based on data obtained with 10 nM ErgTx, very
close to the IC50 determined from the complete
concentration-response relationship (6.5 ± 1.0 nM,
Fig. 4).
The data are summarized in Fig. 5. Most
mutants (30 out of 45) showed little or no change in ErgTx binding
(changes in binding free energy, 
G, less than 0.5 kcal/mol). Of the remaining 15 mutants, three in the S5-P linker
(W585C, G590C, and I593C), and one in the P-S6 linker (P632C) caused
outstanding changes in the binding free energy (>2 kcal/mol). For the
remaining 11 mutants, the changes in binding free energy were modest
although statistically significant (0.5-1 kcal/mol).

View larger version (29K):
[in this window]
[in a new window]
|
Fig. 5.
Effects of cysteine substitutions in the S5-P
and P-S6 linkers of HERG on the potency of ErgTx blockade. In all
cases (except WT) the oocytes were treated with dithiothreitol (5 mM, 0.25-4 h) before recordings. Recordings were conducted
in 98 mM [K]o. Channels were activated by 1-s
depolarization pulses to +20 mV applied once every min, and peak
amplitudes of tail currents at 80 mV were used to monitor effects of
ErgTx (10 nM). Before toxin application, currents were
recorded under the control conditions for 4-9 min to establish a
baseline (Ic). Toxin was then added and mixed with the bath
solution by repetitive pipetting. The toxin effects reached a steady
state in 6-10 min, when Itx was measured. The fraction of
remaining current in the presence of 10 nM ErgTx
(Itx/Ic) was used to estimate the dissociation
constant (Kd) based on modified Equation 1 (assuming
that the maximal toxin effect is 90% reduction of the current, see
Fig. 4): Itx/Ic = 0.9/[1 + [ErgTx]/Kd(V)] + 0.1. The mutation-induced
changes in free energy of toxin binding are calculated based on
Equation 2:  G = RTln(K /K ),
where K and
K are the
Kd values of mutant and WT HERG, respectively
(K = 7.2 ± 1.1 nM, n = 7). Plotted are  G
values (means and S.E. bars, n = 3-7 each) against
channel types along the abscissa. The asterisks
denote mutants whose expression level was too low for measuring ErgTx
effects (N573C, K595C, P605C, N633C, E637C, and K638C). White
bars represent data not different from WT. Gray and
black bars represent data different from WT at
p < 0.05 and p < 0.01, respectively.
W585C, G590C, and P632C were not suppressed even in the presence of 100 nM ErgTx (estimated  G > 3 kcal/mol).
Shown at the top is alignment of partial amino acid
sequences of Shaker and HERG. The putative amphipathic -helix in the
S5-P linker of HERG-(583-595) is shown as an insert and
boxed. The corresponding sequence along the
abscissa is also boxed. Shaded
residues in the Shaker sequence are those important for binding of
ChTx or analog. Shaded residues in the HERG sequence are
those important for ErgTx binding ( G > 2 kcal/mol).
|
|
Fig. 5, top, shows a sequence alignment between Shaker and
HERG in the outer vestibule region. We compare the positions known to
be important for ChTx (or its analog) binding to Shaker or Shaker-like
channels (20, 22-24, 30, 31), with those important for ErgTx binding
to HERG. There are two differences. First, in the Shaker channel, the
positions important for ChTx binding cluster close to the P-loop. In
the HERG channel, the positions in the S5-P linker important for ErgTx
binding are farther away from the P-loop. Second, charge neutralization
in the Shaker channel can have profound effects on ChTx binding (32).
However, this is not the case for ErgTx binding to HERG. Therefore,
neutralizing positively charge residues in the S5-P linker (R582C,
K608C, and K610C) did not enhance ErgTx binding, and neutralizing
negatively charged residues here (E575C, D580C, D591C, and D609C) had
little or only modest effects. Residues that are critical for
ErgTx·HERG interaction are all uncharged. Another important point is
that the three positions in the S5-P linker (Trp-585, Gly-590, and Ile-593) all fall within the putative amphipathic
-helix
(boxed in both the HERG sequence and the abscissa
of Fig. 5). The implications of these findings will be addressed under
"Discussion."
Do Cysteine Mutations Disrupt ErgTx Binding by Inducing Global
Changes in the HERG Outer Vestibule?--
Some of the cysteine
mutations caused a disruption of the C-type inactivation process and
the K+ selectivity of the pore, similar to the phenotype of
H587K shown in Fig. 2A. One such example is shown in Fig.
6B. G590C did not C-type
inactivate or select K+ over Na+
(Erev
15 mV) (left of Fig. 6B). It
could not be suppressed by 10 (or even 100) nM ErgTx (Fig.
6B, right). This is in sharp contrast to the
behavior of WT HERG, which showed a strong C-type inactivation and K:Na
selectivity (Fig. 6A, left) and was strongly
suppressed by ErgTx (10 nM suppressed current by >50%,
Fig. 6A, right). These observations call into
question whether the changes in ErgTx binding resulted from global
changes in the outer vestibule conformation. Fig. 6 (C and
D) suggests that this is not the case. Although D591C could
not C-type inactivate or select K+ over Na+
ions (Erev
20 mV), it retained a high ErgTx
sensitivity (Fig. 6C). On the other hand, Q592C retained
C-type inactivation and a high K:Na selectivity
(Erev
100 mV) but had a significantly lowered
ErgTx sensitivity than WT (Fig. 6D).

View larger version (22K):
[in this window]
[in a new window]
|
Fig. 6.
Lack of correlation between mutation-induced
changes in HERG channel function and changes in ErgTx potency.
Channel types are marked on left. The left column
shows current traces recorded in 2 mM [K]o using
the protocol depicted at the top. The right
column shows current traces recorded before (Ic,
thin traces) and after (Itx, thick or
dotted traces) application of 10 nM ErgTx in 98 mM [K]o using the protocol depicted at the
top.
|
|
ErgTx Binds to the Outer Mouth of HERG and Electrostatic Forces Are
Involved in Toxin Binding--
We suggested above that ErgTx does not
plug the HERG channel pore, as is the case for ChTx blockade of the
Shaker channel. This, in conjunction with the pattern of positions
involved in ErgTx binding to HERG, raises the following question: Does
ErgTx suppress HERG current by binding to the outer mouth region and hindering current flow through the pore or by binding away from the
pore and modifying other channel function, such as gating? In Shaker or
Shaker-like channels, the external TEA binding site overlaps with that
of
-KTx (16). Therefore, TEA binding and
-KTx binding are
mutually exclusive. Fig. 7A
shows that application of 50 mM TEA (~IC50,
Fig. 2B) reduced the degree of WT HERG current suppression
by ErgTx markedly (p < 0.001). This observation
supports an outer mouth binding site for ErgTx.

View larger version (16K):
[in this window]
[in a new window]
|
Fig. 7.
A, effects of an outer mouth blocker,
TEA, on ErgTx (10 nM) blockade of WT HERG.
Itx/Ic was measured as described in Fig. 4 in 2 mM [K]o before and after addition of TEA (50 mM) to the bath solution (with equimolar reduction of
[Na]o, n = 5 and 4 each). B,
effects of changing pHo on ErgTx blockade of WT and mutant HERG
channels. All oocytes expressing cysteine mutants were treated with
dithiothreitol (5 mM, 0.25-4 h) before recordings.
Recordings were conducted in 2 mM [K]o (WT and
H578C) or in 98 mM [K]o (H587C, H578K).
Itx/Ic in ErgTx (10 nM) was
measured as described in Fig. 4, and plotted against pHo
(n = 3-6 each). In most cases, each oocyte was tested
for two or all three pHo conditions in a random order. Shown at
the top is partial HERG amino acid sequence in the outer
vestibule region, with shaded areas highlighting positions
important for ErgTx binding (see Fig. 5). His-578 and His-587 are
marked.
|
|
Do electrostatic forces play any role in ErgTx binding to the HERG
channel? ErgTx has a pI of 7.88 and carries <2 positive charges at pH
7. Fig. 5 further shows that positions in the HERG channel important
for ErgTx binding are all uncharged. Charge neutralization in the
neighboring region had modest or no effect on ErgTx binding. To explore
whether electrostatic forces play any role in ErgTx·HERG interaction,
we altered the net charge on ErgTx by changing the extracellular
solution pH from 7.5 to 8.5 or to 6.5 and examined the resulting
changes in toxin potency. Fig. 7B shows that, for WT HERG,
changing pHo from 7.5 to 8.5 reduced ErgTx potency. This
suggests that net negative charges on ErgTx hindered ErgTx·HERG
binding. Shifting pHo from 7.5 to 6.5 did not affect ErgTx
binding to WT HERG. However, removing either of the two histidines in
the S5-P linker (H578C or H587C) made ErgTx more potent at pHo
6.5. This indicates that protonation of these histidine residues in the
WT HERG channel negated the increased binding affinity of positively
charged ErgTx at pHo 6.5 (probably by increasing the
protonation of H29 of ErgTx, Fig. 1B). On the other hand,
putting a permanent positive charge at position 578 (H578K) reduced
ErgTx potency at pHo 6.5 and 7.5 (when ErgTx should be
positively charged) but not at pHo 8.5 (when ErgTx should be
negatively charged). This is consistent with an electrostatic repulsion
between positive charge at 578 and positive charge on ErgTx at the
lower pHo range that hindered toxin binding. Therefore,
ErgTx·HERG interaction can be influenced by electrostatic forces.
However, the degree of influence is much less for ErgTx·HERG binding
than for ChTx·Shaker binding (32).
Voltage Sensitivity of ErgTx Binding to the HERG
Channel--
Binding of ChTx to the Shaker channel is
voltage-sensitive: Membrane depolarization destabilizes ChTx binding
(16). This voltage sensitivity is exclusively mediated by Lys-27 of
ChTx (16). Although ErgTx does not have a Lys-27-equivalent, previous work has shown that depolarization also reduces ErgTx binding to the
HERG channel (18). It was suggested that this is due to the C-type
inactivation process of the HERG channel at depolarized voltages, which
reduces ErgTx binding. We have confirmed this finding (Fig.
8) and further explored the mechanism.
Fig. 8B summarizes the data and compares it to the voltage
dependence of HERG activation. The steep slope of
Itx/Ic data points in the voltage range of
40
to 0 mV coincides with the voltage range of a steep increase in channel
activation. This suggests that HERG channel activation hinders or
destabilizes ErgTx binding. However, stronger depolarization at the
plateau of the activation curve (>0 mV) further reduced ErgTx binding,
although the slope was less steep than in the negative voltage range.
This decrease in ErgTx binding was not related to C-type inactivation,
because in a mutant that did not C-type inactivate but maintained a
high ErgTx sensitivity (G572C) membrane depolarization still reduced
toxin potency in this voltage range (data not shown). The decrease in
ErgTx binding could not be due to an increase in K+ ion
efflux, because strong depolarization reduced outward current due to
C-type inactivation (Fig. 8A). Finally, this could not be
due to effects of voltage on the binding of a charged ErgTx molecule
within the transmembrane electrical field. As shown in Fig.
8B, the voltage effect was more prominent at pHo 8.5 than at pHo 6.5 ("effective valence" of voltage-sensing domain 0.36 and 0.2 at pHo 8.5 and 6.5, respectively). This is
opposite to the expected effect (e.g. ErgTx should be negatively charged at pHo 8.5 and thus membrane depolarization should enhance ErgTx binding).

View larger version (28K):
[in this window]
[in a new window]
|
Fig. 8.
Voltage dependence of ErgTx blockade of WT
HERG at pHo 6.5 and 8.5. A, representative WT
HERG current traces recorded at specified pHo (in 98 mM [K]o) using the protocol shown in the
inset. The peak amplitudes of tail currents were used to
construct the activation curve and to calculate the fraction of
remaining current in the presence of 10 nM ErgTx
(Itx/Ic). B, comparison of voltage
dependence of WT HERG activation and ErgTx blockade. The relationship
between test pulse voltage (Vt) and tail current
amplitudes (normalized by the tail current amplitude after
Vt to +60 mV) under the control conditions was
fit with a simple Boltzmann function to estimate the half-maximum
activation voltage (V0.5) and slope factor
(k), as shown in the following equation: normalized
tail = 1/[1 + exp((V0.5 Vt)/k)]. The data are shown as
solid symbols based on the right ordinate.
Superimposed curves are calculated using the above equation
with parameter values: pH 6.5, V0.5 = 13.3 ± 0.8 mV, k = 8.8 ± 0.2 mV (n = 4); pH
8.5, V0.5 = 16.0 ± 1.1 mV, k = 9.5 ± 0.4 mV (n = 5). Data of
Itx/Ic are shown as open symbols
based on the left ordinate. The superimposed
lines are calculated based on modified Equation 1 (given in Fig. 5
legend) and the following equation:
Kd(V) = Kd(0)
exp(z VF/RT), where z
denotes the "effective valence" of the voltage-sensing domain that
affects ErgTx binding. For pH 6.5, Kd(0) = 9.7 nM and z = 0.2; for pH 8.5, Kd(0) = 11.5 nM and
z = 0.36.
|
|
 |
DISCUSSION |
Our data suggest that ErgTx binds to the HERG channel with a 1:1
stoichiometry, leading to a suppression of current through the channel
pore. Cysteine-scanning mutagenesis experiments suggest that three
positions in the S5-P linker (Trp-585, Gly-590, and Ile-593) and one
position in the P-S6 linker (Pro-632) are critical determinants of
ErgTx binding. Below we compare the behavior of ErgTx binding to the
HERG channel with that of ChTx (or an analog) binding to the Shaker or
Shaker-like channels. Based on the comparison and what is known about
the mechanism and site of action of ChTx, we further deduce the
mechanism by which ErgTx suppresses HERG currents and the possible
location of ErgTx receptor site on the HERG channel.
There are some apparent similarities in the behavior of binding of
ErgTx and ChTx to their target channels: 1) TEA, an outer mouth
blocker, can antagonize toxin binding in both cases. This supports the
notion that ErgTx binds to the outer mouth of HERG, and the binding
site overlaps with that of TEA. 2) Electrostatic forces are involved in
toxin binding in both cases, although to different degrees. In the case
of ChTx binding to the Shaker channel, electrostatic forces play a
major role in toxin binding and pore blockade. ChTx has a pI value of
9.03 and carries about six positive charges at pH 7. Negative charges
around the receptor site help orient the toxin in binding to the
receptor (32). Furthermore, the lysine at position 27 of ChTx (Lys-27)
binds within the pore and occludes current through the channel (16,
22). The pHo experiments shown in Fig. 7B suggest
that charge-charge interactions also matter in ErgTx binding to the
HERG channel. However, such charge-charge interactions are not a major
factor in ErgTx binding to HERG. This is not surprising, because ErgTx
has a pI value of 7.88 and carries less than two positive charges at pH
7. Furthermore, ErgTx does not have a positive charge equivalent to
Lys-27 in ChTx. 3) Membrane depolarization reduces toxin binding in
both cases but likely by different mechanisms. Membrane depolarization destabilizes ChTx binding by two mechanisms, both of which are mediated
by Lys-27. First, depolarization enhances K+ ion occupancy
inside the pore by promoting
K
ion efflux. This can
dislodge ChTx bound to the pore through electrostatic repulsion between
K+ ions and Lys-27. Second, Lys-27 of bound ChTx senses
~20% of the transmembrane electrical field. Therefore, membrane
depolarization can have a direct effect on Lys-27 and thus ChTx
binding. ErgTx does not have a Lys-27-equivalent. Furthermore, our data
in Fig. 8 show that the destabilization effect of membrane
depolarization was more pronounced at pHo 8.5 (ErgTx negatively
charged) than at pHo 6.5 (ErgTx positively charged). This
observation rules out the possibility that membrane depolarization
destabilizes ErgTx binding by a direct effect on a charged ErgTx
molecule bound within the transmembrane electrical field. We propose
that conformational changes in the S5-P linker during strong membrane
depolarization hinder or destabilize ErgTx binding.
There are distinct differences in the behavior of toxin/channel
interactions: 1) Elevating [K]o destabilizes ChTx binding to
Shaker (16, 22), but does no affect ErgTx binding to HERG. The effect
of changing [K]o on ChTx·Shaker interaction is exclusively
mediated by Lys-27 (16, 22). The insensitivity of ErgTx·HERG
interaction to elevating [K]o is consistent with the notion
that ErgTx does not have an Lys-27-equivalent. 2) The pattern of
positions important for toxin-channel interaction differs between the
two (Fig. 5, top). Positions important for ChTx binding to
the Shaker channel are those flanking the pore loop, with positions
farther away from the pore loop having decreasing importance in
influencing toxin binding (22, 23). For ErgTx·HERG, the positions in
the S5-P linker important for toxin binding are far away from the pore
loop in one-dimensional sequence. Charge mutations in Shaker have
marked effects on ChTx binding (31, 32) but little or no effects on
ErgTx binding to the HERG channel.
What can we conclude about the mechanism by which ErgTx suppresses the
HERG current? We can conclude that ErgTx binds to the outer vestibule
of HERG, but it probably does not plug the pore with a positive charge
as is the case for Lys-27 in ChTx. The maximal effect of ErgTx is
~90% suppression of the HERG current, not 100%. Again, this is
consistent with the notion that ErgTx is not a "molecular plug" of
the HERG pore. This situation is similar to
-dendrotoxin suppression
of ShaKv1.1:
-Dendrotoxin does not physically plug the pore but
binds in an "off-center" position in the outer vestibule. This
leads to a reduction, but not a total occlusion, of current through the
pore (33).
What can we learn about the ErgTx receptor site on the HERG channel?
The cysteine-scanning mutagenesis data suggest that S5-P and P-S6
linkers are both involved. Although these two domains are not
contiguous in one-dimensional sequence, in three-dimensional space, the
long (43 amino acids) S5-P linker of HERG may come close to the P-S6
linker and thus to the channel pore. Our working hypothesis is
illustrated by the schematic in Fig.
9A. An analysis of possible
secondary structures in the S5-P linker using the program, Protean, in
LaserGene (34) suggests that positions 583-594 may form an amphipathic
-helix. The helical wheel plot in Fig. 9B shows that
hydrophobic residues is this region cluster to one face of the
-helix, among which Trp-585, Gly-590, and Ile-593 may form contact
points with bound ErgTx. The other face of the
-helix has mainly
hydrophilic residues. This face of the
-helix is not involved in
ErgTx binding, because neutralizing the negative charge here, D591C,
has no effects on toxin binding (Figs. 5 and 6).

View larger version (34K):
[in this window]
[in a new window]
|
Fig. 9.
A proposed outer vestibule structure for the
HERG channel. A, two-dimensional schematic of an HERG
subunit, showing the putative -helix formed by residues 583-594 in
the S5-P linker that comes in close contact with the P-S6 linker.
B, helical wheel plot of residues 583-594, viewed from the
N-terminal end. Five residue numbers are labeled for reference. Note
that positions important for ErgTx binding cluster to the hydrophobic
face of the amphipathic -helix.
|
|
In summary, we show that the long S5-P linker of the HERG channel
contributes importantly to the outer mouth properties of this channel,
supporting the conclusion from a previous report (19). We propose that
this linker can engage in intimate interactions with the pore's
entryway and participates in conformational changes important for the
C-type inactivation process and for K:Na selectivity of the pore.
Future work will be focused on identifying toxin and channel residues
interacting across the toxin-channel interface. This, in conjunction
with ErgTx's solution structure obtained by the NMR technique, will
yield a three-dimensional structure of the outer vestibule of the HERG channel.
 |
FOOTNOTES |
*
This study was supported by Grant HL 46451 from NHLBI,
National Institutes of Health, and a Grant-in-Aid from the American Heart Association/Mid-Atlantic Affiliate (to G. N. T.) and by grants
from Howard Hughes Medical Institute (Grant 55000574), the National
Council of Science & Technology of Mexico (Grant 31691-N), and the
National Autonomous University of Mexico (Grant IN216900) (to
L. D. P.).The costs of publication of this
article were defrayed in part by the
payment of page charges. The article must therefore be hereby marked
"advertisement" in
accordance with 18 U.S.C. Section
1734 solely to indicate this fact.
¶
To whom correspondence should be addressed: Dept. of
Physiology, Virginia Commonwealth University, 1101 E. Marshall St.,
Richmond, VA 23298. Tel.: 804-827-0811; Fax: 804-828-7382; E-mail:
gtseng@hsc.vcu.edu.
Published, JBC Papers in Press, February 25, 2002, DOI 10.1074/jbc.M200460200
 |
ABBREVIATIONS |
The abbreviations used are:
IKr, rapid delayed rectifier;
HERG, human
ether-a-go-go-related gene;
ErgTx, HERG-specific peptide
toxin;
ChTx, charybdotoxin;
LQT, long QT syndrome;
WT, wild-type;
TEA, tetraethylammonium.
 |
REFERENCES |
| 1.
|
Tseng, G.-N.
(2001)
J. Mol. Cell Cardiol.
33,
835-849[CrossRef][Medline]
[Order article via Infotrieve]
|
| 2.
|
Sanguinetti, M. C.,
Jiang, C.,
Curran, M. E.,
and Keating, M. T.
(1995)
Cell
81,
299-307[CrossRef][Medline]
[Order article via Infotrieve]
|
| 3.
|
Roden, D. M.,
and Balser, J. R.
(1999)
Cardiovasc. Res.
44,
242-246[Free Full Text]
|
| 4.
|
Ficker, E.,
Jarolimek, W.,
Kiehn, J.,
Baumann, A.,
and Brown, A. M.
(1998)
Circ. Res.
82,
386-395[Abstract/Free Full Text]
|
| 5.
|
Wang, S.,
Morales, M. J.,
Liu, S.,
Strauss, H. C.,
and Rasmusson, R. L.
(1997)
FEBS Lett.
417,
43-47[CrossRef][Medline]
[Order article via Infotrieve]
|
| 6.
|
Numaguchi, H.,
Mullins, F. M.,
Johnson, J. P. J.,
Johns, D. C., Po, S. S.,
Yang, I. C. H.,
Tomaselli, G. F.,
and Balser, J. R.
(2000)
Circ. Res.
87,
1012-1018[Abstract/Free Full Text]
|
| 7.
|
Smith, P. L.,
Baukrowitz, T.,
and Yellen, G.
(1996)
Nature
379,
833-836[CrossRef][Medline]
[Order article via Infotrieve]
|
| 8.
|
MacKinnon, R.,
Reinhart, P. H.,
and White, M. M.
(1988)
Neuron
1,
997-1001[CrossRef][Medline]
[Order article via Infotrieve]
|
| 9.
|
Doyle, D. A.,
Cabral, J. M.,
Pfuetzner, R. A.,
Kuo, A.,
Gulbis, J. M.,
Cohen, S. L.,
Chait, B. T.,
and MacKinnon, R.
(1998)
Science
280,
69-77[Abstract/Free Full Text]
|
| 10.
|
Rauer, H.,
Lanigan, M. D.,
Pennington, M. W.,
Aiyar, J.,
Ghanshani, S.,
Cahalan, M. D.,
Norton, R. S.,
and Chandy, K. G.
(2000)
J. Biol. Chem.
275,
1201-1208[Abstract/Free Full Text]
|
| 11.
|
Spector, P. S.,
Curran, M. E.,
Zou, A.,
Keating, M. T.,
and Sanguinetti, M. C.
(1996)
J. Gen. Physiol.
107,
611-619[Abstract/Free Full Text]
|
| 12.
|
Dun, W.,
Jiang, M.,
and Tseng, G.-N.
(1999)
Pflugers Archiv.
439,
141-149[CrossRef][Medline]
[Order article via Infotrieve]
|
| 13.
|
Possani, L. D.,
Selisko, B.,
and Gurrola, G. B.
(1999)
Perspect. Drug Disc. Des.
15/16,
15-40[CrossRef]
|
| 14.
|
Garcia, M. L.,
Gao, Y.-D.,
McManus, O. B.,
and Kaczorowski, G. J.
(2001)
Toxicon.
39,
739-748[Medline]
[Order article via Infotrieve]
|
| 15.
|
Tytgat, J.,
Chandy, K. G.,
Garcia, M. L.,
Gutman, G. A.,
Martin-Eauclaire, M.-F.,
van der Walt, J. J.,
and Possani, L. D.
(1999)
Trends Pharmacol. Sci.
20,
444-447[CrossRef][Medline]
[Order article via Infotrieve]
|
| 16.
|
Goldstein, S. A. N.,
and Miller, C.
(1993)
Biophys. J.
65,
1613-1619[Abstract/Free Full Text]
|
| 17.
|
Scaloni, A.,
Bottiglieri, C.,
Ferrara, L.,
Corona, M.,
Gurrola, G. B.,
Batista, C.,
Wanke, E.,
and Possani, L. D.
(2000)
FEBS Lett.
479,
155-157[CrossRef][Medline]
[Order article via Infotrieve]
|
| 18.
|
Gurrola, G. B.,
Rosati, B.,
Rocchetti, M.,
Pimienta, G.,
Zaza, A.,
Arcangeli, A.,
Olivotto, M.,
Possani, L. D.,
and Wanke, E.
(1999)
FASEB J.
13,
953-962[Abstract/Free Full Text]
|
| 19.
|
Pardo-Lopez, L.,
Garcia-Valdes, J.,
Gurrola, G. B.,
Robertson, G. A.,
and Possani, L. D.
(2002)
FEBS Lett.
510,
45-49[CrossRef][Medline]
[Order article via Infotrieve]
|
| 20.
|
Hidalgo, P.,
and MacKinnon, R.
(1995)
Science
268,
307-310[Abstract/Free Full Text]
|
| 21.
|
Stocker, M.,
and Miller, C.
(1994)
Proc. Natl. Acad. Sci. U. S. A.
91,
9509-9513[Abstract/Free Full Text]
|
| 22.
|
Ranganathan, R.,
Lewis, J. H.,
and MacKinnon, R.
(1996)
Neuron
16,
131-139[CrossRef][Medline]
[Order article via Infotrieve]
|
| 23.
|
Goldstein, S. A. N.,
Pheasant, D. J.,
and Miller, C.
(1994)
Neuron
12,
1377-1388[CrossRef][Medline]
[Order article via Infotrieve]
|
| 24.
|
Gross, A.,
and MacKinnon, R.
(1996)
Neuron
16,
399-406[CrossRef][Medline]
[Order article via Infotrieve]
|
| 25.
|
Tseng-Crank, J. C. L.,
Tseng, G.-N.,
Schwartz, A.,
and Tanouye, M. A.
(1990)
FEBS Lett.
268,
63-68[CrossRef][Medline]
[Order article via Infotrieve]
|
| 26.
|
Schreibmayer, W.,
Lester, H. A.,
and Dascal, N.
(1994)
Pflugers Archiv.
426,
453-458[CrossRef][Medline]
[Order article via Infotrieve]
|
| 27.
|
Jiang, M.,
Dun, W.,
and Tseng, G.-N.
(1999)
Am. J. Physiol.
277,
H1283-H1292[Abstract/Free Full Text]
|
| 28.
|
Heginbotham, L.,
and MacKinnon, R.
(1992)
Neuron
8,
483-491[CrossRef][Medline]
[Order article via Infotrieve]
|
| 29.
|
Fan, J.-S.,
Jiang, M.,
Dun, W.,
McDonald, T. V.,
and Tseng, G.-N.
(1999)
Biophys. J.
76,
3128-3140[Abstract/Free Full Text]
|
| 30.
|
Naranjo, D.,
and Miller, C.
(1996)
Neuron
16,
123-130[CrossRef][Medline]
[Order article via Infotrieve]
|
| 31.
|
MacKinnon, R.,
Heginbotham, L.,
and Abramson, T.
(1990)
Neuron
5,
767-771[CrossRef][Medline]
[Order article via Infotrieve]
|
| 32.
|
MacKinnon, R.,
and Miller, C.
(1989)
Science
245,
1382-1385[Abstract/Free Full Text]
|
| 33.
|
Imredy, J. P.,
and MacKinnon, R.
(2000)
J. Mol. Biol.
296,
1283-1294[CrossRef][Medline]
[Order article via Infotrieve]
|
| 34.
|
Eisenberg, D.,
Weiss, R. M.,
and Terwilliger, T. C.
(1984)
Proc. Natl. Acad. Sci. U. S. A.
81,
140-144[Abstract/Free Full Text]
|